Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies that target the CD40 Ligand (CD40L) pathway. Its lead compound, tegoprubart, is an IgG1 anti-CD40L antibody designed to prevent organ transplant rejection and treat amyotrophic lateral sclerosis (ALS). The company is also exploring tegoprubart for xenotransplantation and has a collaboration with eGenesis, Inc. Additionally, Eledon has a strategic collaboration with NewcelX Ltd. to develop NCEL-101 for Type 1 Diabetes. Formerly known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.

Eledon Pharmaceuticals is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ELDN. The company trades in US Dollars (USD), as it is based in the United States. The NasdaqCM is a US-based exchange that lists smaller-cap companies, and Eledon's listing there provides liquidity for investors interested in the biotechnology sector.

Eledon Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies using biological processes. In Eledon's case, its work centers on the CD40L pathway to create treatments for transplant rejection, ALS, and other conditions. Biotechnology companies like Eledon often have long development timelines and require significant investment in clinical trials.

Eledon Pharmaceuticals is headquartered in Irvine, California, United States. As a clinical-stage biotechnology company, its primary focus is on developing therapies for global markets, particularly in the areas of organ transplantation and neurodegenerative diseases. The company's collaborations with eGenesis (for xenotransplantation) and NewcelX (for Type 1 Diabetes) indicate a reach beyond the US, aiming to address medical needs worldwide. However, specific market details beyond its US base are not provided in the available data.

Eledon Pharmaceuticals is a clinical-stage biotechnology company, meaning it does not yet have approved products on the market and currently generates no revenue from product sales. Its business model involves advancing its lead candidate, tegoprubart, through clinical trials to obtain regulatory approval for indications such as kidney transplant rejection and ALS. The company also leverages strategic collaborations, such as those with eGenesis and NewcelX, to share development costs and expertise. Revenue, if any, would come from collaboration payments or milestone achievements, but the primary focus remains on research and development until potential commercialization.